Related Experiment Video
Updated: Nov 7, 2025
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
Bioinformatic analysis linking genomic defects to chemosensitivity and mechanism of action
1Information Technologies Branch, Developmental Therapeutics Program, National Cancer Institute, Frederick, MD, United States of America.
Abstract:
A joint analysis of the NCI60 small molecule screening data, their genetically defective genes, and mechanisms of action (MOA) of FDA approved cancer drugs screened in the NCI60 is proposed for identifying links between chemosensitivity, genomic defects and MOA. Self-Organizing-Maps (SOMs) are used to organize the chemosensitivity data. Student's t-tests are used to identify SOM clusters with enhanced chemosensitivity for tumor cell lines with versus without genetically defective genes. Fisher's exact and chi-square tests are used to reveal instances where defective gene to chemosensitivity associations have enriched MOAs. The results of this analysis find a relatively small set of defective genes, inclusive of ABL1, AXL, BRAF, CDC25A, CDKN2A, IGF1R, KRAS, MECOM, MMP1, MYC, NOTCH1, NRAS, PIK3CG, PTK2, RPTOR, SPTBN1, STAT2, TNKS and ZHX2, as possible candidates for roles in chemosensitivity for compound MOAs that target primarily, but not exclusively, kinases, nucleic acid synthesis, protein synthesis, apoptosis and tubulin. These results find exploitable instances of enhanced chemosensitivity of compound MOA's for selected defective genes. Collectively these findings will advance the interpretation of pre-clinical screening data as well as contribute towards the goals of cancer drug discovery, development decision making, and explanation of drug mechanisms.
Insights
This study links cancer drug effectiveness to specific gene defects using NCI60 screening data. Identifying these links aids in cancer drug discovery and understanding drug mechanisms.
Area of Science:
- Genomics
- Pharmacology
- Bioinformatics
Background:
- The NCI60 cell line panel is a valuable resource for cancer drug screening.
- Understanding the relationship between genetic defects, drug sensitivity, and drug mechanisms is crucial for effective cancer therapy.
- Current methods for analyzing complex screening data can be improved.
Purpose of the Study:
- To identify associations between genetic defects and chemosensitivity in cancer cell lines.
- To explore the relationship between these genetic defects, drug sensitivity, and the mechanisms of action (MOA) of FDA-approved cancer drugs.
- To enhance the interpretation of pre-clinical cancer drug screening data.
Main Methods:
- Joint analysis of NCI60 small molecule screening data, genetic defect information, and drug mechanisms of action.
- Utilizing Self-Organizing Maps (SOMs) for organizing and clustering chemosensitivity data.
- Employing statistical tests (Student's t-tests, Fisher's exact, chi-square) to identify significant associations between genetic defects, chemosensitivity, and drug MOAs.
Main Results:
- A specific set of 19 defective genes (e.g., ABL1, BRAF, KRAS, MYC) were identified as potential key players in chemosensitivity.
- These genes showed associations with drug MOAs targeting kinases, nucleic acid and protein synthesis, apoptosis, and tubulin.
- Exploitable instances of enhanced chemosensitivity were found for specific defective genes and compound MOAs.
Conclusions:
- The findings provide a framework for linking chemosensitivity to genomic defects and drug MOA.
- This analysis advances the interpretation of pre-clinical screening data for cancer drug discovery.
- The results contribute to better decision-making in drug development and a deeper explanation of drug mechanisms.
More Related Videos
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
10:05Genome-wide Mapping of Drug-DNA Interactions in Cells with COSMIC Crosslinking of Small Molecules to Isolate Chromatin
Published on: January 20, 2016
